Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
The following slide deck was published by UCB SA in conjunction with their 2020 Q2 earnings Read more ...
- UCB's resilient product portfolio drives continued company growth BRUSSELS , July 27, 2020 /PRNewswire/ -- Revenue increased to € 2.6 billion and net sales to € 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively Unde...
ATLANTA and PARSIPPANY, N.J. , July 7, 2020 /PRNewswire/ -- UCB and Ferring Pharmaceuticals Inc. today announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA ® (certolizumab pegol) in the United State...
BRUSSELS , June 12, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the Americ...
Underlines UCB's leadership in epilepsy by adding Staccato ® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure Staccato ® Alprazolam could be a potential solution for 20...
Update on attendance and voting instructions relating to UCB's General Meeting of 30 April 2020 Implementation of Royal Decree n°4 of 9 April 2020 on various provisions regarding the legislation on co-ownership and companies and associations, in the framework of the fight aga...
- The transaction, which was announced October 10, 2019 , will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab , UCB's FcRn target...
Background According to a recent study by Gartner, average duration to finalize a merger or acquisition from the time of public announcement has risen more than 30 percent in the last decade. Gartner analyzed more than 23000 deals among S&P1200 companies since 2010 to come up with th...
UCB SA (UCBJF) Q4 2019 Earnings Conference Call February 20, 2020 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO & Executive Director Emmanuel Caeymaex - EVP & Head, Immunology Patient Value Unit Detlef Thielgen - CFO & EVP Cha...
The following slide deck was published by UCB SA in conjunction with their 2019 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price! PR Newswire Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi announce the fu...
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...